NCT00237289 – Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting Posted on October 20, 2014 by tsuperadmin -
NCT00266552 – The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Posted on October 20, 2014 by tsuperadmin -
NCT00250354 – The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Posted on October 20, 2014 by tsuperadmin -
NCT00236470 – Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders – an Open Label Follow-up Trial of CR002020 Posted on October 20, 2014 by tsuperadmin -
NCT00236444 – Risperidone in the Prevention of Relapse: a Randomized, Double-blind, Placebo-controlled Trial in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders Posted on October 20, 2014 by tsuperadmin -
NCT00412373 – A Randomized, Double-blind, Placebo-controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Flexible-dose Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder Posted on October 20, 2014 by tsuperadmin -
NCT00397033 – A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Two Dosages of Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder Posted on October 20, 2014 by tsuperadmin -
NCT00269815 – Long-term Safety and Effectiveness of OROS (Methylphenidate HCl) in Children With ADHD Posted on October 20, 2014 by tsuperadmin -
NCT00866996 – A Multi-center Randomized Parallel Group Study Evaluating Treatment Outcomes of Concerta (Extended Release Methylphenidate) and Strattera (Atomoxetine) in Children With Attention-deficit/Hyperactivity Disorder Posted on October 20, 2014 by tsuperadmin -
NCT00714688 – A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS Methylphenidate (54 and 72 mg/Day) in Adults With Attention Deficit/Hyperactivity Disorder Posted on October 13, 2014 by tsuperadmin -
The YODA Project